caa a22 4500 445314109 CHVBK 20180317142640.0 cr unu---uuuuu 170323e20110201xx s 000 0 eng 10.1007/s11095-010-0178-7 doi (NATIONALLICENCE)springer-10.1007/s11095-010-0178-7 Clinical Developments in Nanotechnology for Cancer Therapy [Elektronische Daten] [Jeremy Heidel, Mark Davis] ABSTRACT: Nanoparticle approaches to drug delivery for cancer offer exciting and potentially "game-changing” ways to improve patient care and quality of life in numerous ways, such as reducing off-target toxicities by more selectively directing drug molecules to intracellular targets of cancer cells. Here, we focus on technologies being investigated clinically and discuss numerous types of therapeutic molecules that have been incorporated within nanostructured entities such as nanoparticles. The impacts of nanostructured therapeutics on efficacy and safety, including parameters like pharmacokinetics and biodistribution, are described for several drug molecules. Additionally, we discuss recent advances in the understanding of ligand-based targeting of nanoparticles, such as on receptor avidity and selectivity. Springer Science+Business Media, LLC, 2010 clinical nationallicence nanoparticle nationallicence oncology nationallicence pharmacokinetics nationallicence targeting nationallicence Heidel Jeremy Calando Pharmaceuticals, Pasadena, California, USA aut Davis Mark Chemical Engineering, California Institute of Technology, M/C 210-41, Pasadena, California, USA aut Pharmaceutical Research Springer US; http://www.springer-ny.com 28/2(2011-02-01), 187-199 0724-8741 28:2<187 2011 28 11095 https://doi.org/10.1007/s11095-010-0178-7 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11095-010-0178-7 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Heidel Jeremy Calando Pharmaceuticals, Pasadena, California, USA aut NATIONALLICENCE 700 1- Davis Mark Chemical Engineering, California Institute of Technology, M/C 210-41, Pasadena, California, USA aut NATIONALLICENCE 773 0- Pharmaceutical Research Springer US; http://www.springer-ny.com 28/2(2011-02-01), 187-199 0724-8741 28:2<187 2011 28 11095 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer